Foresee Pharmaceuticals
Biotechnology, Holzkirchen, Bavaria, Taiwan, Province of China, 51-200 Employees
Phone Number: +13*********
Who is FORESEE PHARMACEUTICALS
Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange(TPEx:6576). Foresee's R&D efforts are focused in two key areas, namely its unique ...
Read More
-
Headquarters: Holzkirchen, Bavaria, Taiwan, Province of China
-
Date Founded: 2013
-
Employees: 51-200
-
Revenue: $1 Billion and Over
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from FORESEE PHARMACEUTICALS
Foresee Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Foresee Pharmaceuticals
Answer: Foresee Pharmaceuticals's phone number is +13*********
Answer: Foresee Pharmaceuticals's official website is https://foreseepharma.com
Answer: Foresee Pharmaceuticals's revenue is $1 Billion and Over
Answer: Foresee Pharmaceuticals's SIC: 2834
Answer: Foresee Pharmaceuticals's NAICS: 325412
Answer: Foresee Pharmaceuticals has 51-200 employees
Answer: Foresee Pharmaceuticals is in Biotechnology
Answer: Foresee Pharmaceuticals contact info: Phone number: +13********* Website: https://foreseepharma.com
Answer: Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange(TPEx:6576). Foresee's R&D efforts are focused in two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee's product portfolio includes late and early-stage programs. CAMCEVI 42 mg, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU and Taiwan and launched in the U.S. in April 2022. Additionally, U.S. and EU regulatory submissions are under preparation for CAMCEVI 21 mg. For the second indication of CAMCEVI 42 mg, central precocious puberty (CPP), the Phase 3 clinical study, has been initiated. FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study has been completed with positive outcomes, with future development in rare immune-fibrotic diseases. FP-045 is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 Fanconi Anemia study is currently being initiated, and a Phase 2 study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is in planning.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month